News

Blood-Based Diagnostic Assay Measures Immunotherapy Biomarker PD-L1

Monday, February 27, 2017

ddPCR Assay Measures mRNA Expressions from Immune and Cancer Cell; Key Step in Development of Immunotherapy Test  

Anders Hove, MD Joins ARCA biopharma Board of Directors

Tuesday, February 21, 2017

WESTMINSTER, Colo.--(BUSINESS WIRE)--ARCA biopharma, Inc. (Nasdaq: ABIO), a biopharmaceutical company applying a precision medicine approach to developing genetically-targeted therapies for cardiovascular diseases, today announced that Anders Hove, M.D., has joined its Board of Directors.

“Anders brings decades of experience building and advising biopharmaceutical companies,” said Dr. Michael R. Bristow, President and Chief Executive Officer of ARCA. “With his expertise on both the corporate and investment sides of the industry, Anders’ input and guidance will be valuable to our Board of Directors as we continue the development of Gencaro and seek to deliver value to our stockholders.”

 
Continue Reading

Health-Tech Innovators Advocate For Colorado’s Advanced Industries Grants

Tuesday, February 21, 2017

DENVER, Colo. – A culture of collaboration has made Colorado the #1 Health Innovation ecosystem in the United States today.

Organizations like Prime Health, the Colorado Bioscience Association (CBSA), Innosphere and the Office of Economic Development and International Trade (OEDIT), are working on behalf of the ecosystem to support programs and funding that drive innovation and acceleration commercialization.

One of the qualities that make Colorado unique for entrepreneurs is the publicly supported advanced industries grants and tax credits run by OEDIT. These programs encourage private investors to provide funding for local companies with high growth potential.

Full story at CyberMed News

 
Continue Reading

MiRagen raises $40.7 million, goes public with Signal Genetics merger

Tuesday, February 14, 2017

BOULDER — Clinical-stage biopharmaceutical company MiRagen Therapeutics Inc. has completed its merger with a publicly traded California company, raising $40.7 million in private equity financing just prior to the deal. MiRagen begins trading Tuesday on the Nasdaq exchange under the ticker symbol “MGEN.” 

Aytu BioScience Provides Second Quarter Fiscal 2017 Business Update and Financial Results

Friday, February 10, 2017

Aytu BioScience, Inc. (AYTU), a specialty pharmaceutical company focused on global commercialization of novel products in the field of urology, today provided an overview of its business and growth strategy, as well as its financial results, for the second quarter of fiscal 2017, ended December 31, 2016. The Company will host a live conference call and webcast today at 4:30 p.m. ET, details are provided at the end of this press release. 

Biodesix GeneStrat Liquid Biopsy Testing™ Now Includes ROS1 and RET Mutations

Thursday, February 02, 2017

BOULDER, Colo.--(BUSINESS WIRE)--Biodesix®, Inc. announced today that the GeneStrat® test, a liquid biopsy for patients with cancer, now includes ROS1 and RET in addition to EGFR sensitizing; EGFR resistance (T790M), KRAS, BRAF mutations; and EML4-ALK fusions. GeneStrat is a non-invasive blood test analyzing circulating tumor DNA and RNA. The test provides fast, highly sensitive results in 72 hours for non-small cell lung cancer (NSCLC) patients. Ongoing clinical validation and concordance studies for the actionable mutations are summarized at http://www.biodesix.com/genestrat/?sc=pr

Physicians can utilize GeneStrat as part of the Biodesix Lung Reflex™ multi-omic, liquid biopsy testing strategy when reflexed to VeriStrat® proteomic testing, to identify more aggressive tumor growth and inform likely patient benefit from treatment. In 2016, nearly 80% of physicians who ordered GeneStrat chose to reflex to VeriStrat testing. The VeriStrat test and the genes tested in GeneStrat are covered by Medicare and many private payers.

 
Continue Reading

Cetya Therapeutics Announces Investment

Wednesday, February 01, 2017

$25,000 investment from Colorado Institute for Drug, Device and Diagnostic Development will advance oncology drug development 

National PKU Alliance partners with Baby Genes

Wednesday, February 01, 2017

The National PKU Alliance (NPKUA) has partnered with Baby Genes Inc. to assist hundreds of people diagnosed with Phenylketonuria (PKU) obtain simple and affordable access to mutation analysis of the PAH gene responsible for PKU. PKU is an inherited metabolic disorder that is diagnosed at birth through newborn screening. Baby Genes’ full gene sequencing technology provides accurate, efficient results identifying specific mutations associated with PKU. Test results will be made available in 96 hours after testing has started. Currently, access to mutation analysis is not standard of care in this rare disease. 

Clovis Oncology and Strata Oncology Announce Collaboration to Accelerate Enrollment in Rucaparib Prostate Cancer Development Program

Wednesday, February 01, 2017

BOULDER, Colo. & ANN ARBOR, Mich.--(BUSINESS WIRE)--Clovis Oncology, Inc. (NASDAQ: CLVS) and Strata Oncology, Inc. today announced an agreement to accelerate patient identification and enrollment for Clovis’ ongoing TRITON (Trial of Rucaparib in Prostate Indications) clinical trial program, which includes Phase 2 and Phase 3 clinical trials of rucaparib in metastatic castration-resistant prostate cancer, both of which are open for enrollment.